A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(25 sites)

United States

Southern California Research Center, Coronado, California

Velocity Clinical Research, San Diego, La Mesa, California

Kaiser Permanente - Los Angeles Medical Center, Los Angeles, California

Catalina Research Institute, LLC, Montclair, California

Peak Gastroenterology Associates, Colorado Springs, Colorado

Schiff Center Liver Diseases, Miami, Florida

Panax Clinical Research, Miami Lakes, Florida

Covenant Metabolic Specialists, LLC - University Park, University Park, Florida

Centricity Research Columbus Georgia Multispecialty, Columbus, Georgia

University of Iowa Hospitals and Clinics, Iowa City, Iowa

University of Kansas Medical Center, Kansas City, Kansas

Johns Hopkins Hospital, Baltimore, Maryland

Mayo Clinic, Rochester, Rochester, Minnesota

Columbia University Medical Center, New York, New York

Lucas Research, Inc., Morehead City, North Carolina

Medical University of South Carolina, Charleston, South Carolina

Nashville General Hospital, Nashville, Tennessee

Texas Clinical Research Institute, LLC, Arlington, Texas

Epic Medical Research - Carrollton, Carrollton, Texas

The Liver Institute at Methodist Dallas, Dallas, Texas

Epic Medical Research - Fort Worth, Fort Worth, Texas

Houston Methodist Hospital, Houston, Texas

Pioneer Research Solutions, Inc., Houston, Texas

American Research Corporation at the Texas Liver Institute, San Antonio, Texas

Canada

University of Alberta Hospital (University of Alberta), Edmonton, Alberta